In 1994, the innovative minds of a research group at the University of Munich, led by Amgen vice president Dr. Peter Kufer, made a monumental discovery. Aiming to use the human immune system to fight cancer cells, Dr. Kufer’s team invented Bispecific T-cell Engager (BiTE®) technology.
During this Gastric Cancer Awareness Month (GCAM), watch Essie Graeber’s courageous journey through her diagnosis and treatment of gastric cancer.
Amgen’s DNA-encoded library platform helps researchers screen billions of compounds to fuel the search for new small molecule therapies.
Discover an emerging protein biomarker in gastric cancer, FGFR2b, gastric cancer biomarkers, FGFR2b protein overexpression, biomarker detection considerations, and more.
To produce safe, accurate output, large language models (LLMs) must be trained on accurate information. In this study, researchers simulated a data-poisoning attack by implanting…
Join us in Baltimore on April 7-8 to collaborate and share best practices for some of the most pressing issues in health care quality.
The National Healthcare Safety Dashboard is a critical part of our broader National Action Alliance (NAA) for Patient and Workforce Safety. The NAA is a…
Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line…
Miscommunication is a major contributor to adverse events. This article describes the development of a framework to classify communication errors that contributed to a patient…
The VersaCross RF Transseptal Platform was designed to simplify your workflow and improve puncture efficacy. Every VersaCross Solution includes the 3-in-1 VersaCross RF Wire, with…
U.S. News & World Report, AAFP tally colleges with physician alumni working in family, internal, and pediatric medicine.
